{
    "id": 414,
    "fullName": "TP53 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type TP53 indicates that no mutation has been detected within the TP53 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7157,
        "geneSymbol": "TP53",
        "terms": [
            "TP53",
            "BCC7",
            "BMFS5",
            "LFS1",
            "P53",
            "TRP53"
        ]
    },
    "variant": "wild-type",
    "createDate": "04/24/2014",
    "updateDate": "08/29/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10681,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2328,
                "therapyName": "MK-8745",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8741,
                    "pubMedId": 22293494,
                    "title": "The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22293494"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10015,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a lung carcinoma cell line harboring wild-type TP53 in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 5346,
                "therapyName": "AZD6738 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7909,
                    "pubMedId": 28062704,
                    "title": "Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28062704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18038,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial,  KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 83.3% (10/12) of patients with TP53 wild-type ER-positive breast cancer (BC), with a median duration of 2.0 months in ER-positive, PR-positive BC, 1.4 months in ER-positive, PR-negative BC, and one patient achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8091,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) induced activation of Tp53 target genes and inhibited growth of several human tumor cell lines with wild-type TP53 in culture and in cell line xenograft models (PMID: 25567130).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18034,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 80% (31/39) of patients with TP53 wild-type advanced solid tumors, with a median duration of 3.1 months (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9317,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO6839921 and Cytosar-U (cytarabine) combination treatment demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4968,
                "therapyName": "Cytarabine + RO6839921",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7077,
                    "pubMedId": null,
                    "title": "Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11089,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with liposarcoma (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9071,
                    "pubMedId": null,
                    "title": "Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187803.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1134,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 878,
                    "pubMedId": 24231268,
                    "title": "BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24231268"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1791,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 inhibited growth of TP53 wild-type colon cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1886,
                    "pubMedId": 25145672,
                    "title": "SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25145672"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11082,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9071,
                    "pubMedId": null,
                    "title": "Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187803.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1789,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 inhibited growth of TP53 wild-type acute leukemia cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 12603,
                "name": "acute leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1886,
                    "pubMedId": 25145672,
                    "title": "SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25145672"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1126,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775), in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1566,
                "therapyName": "Adavosertib + PF-00477736",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 394,
                    "pubMedId": 22713237,
                    "title": "Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22713237"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4206,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3458,
                "therapyName": "MPI-0479605",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4435,
                    "pubMedId": 21980130,
                    "title": "Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21980130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5584,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3900,
                "therapyName": "CTX-1 + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5110,
                    "pubMedId": 26883273,
                    "title": "Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26883273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7840,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Trifluridine (FTD) resulted in Tp53-dependent cell-cycle arrest and decreased expression of CyclinB1 and Cdk1 in a Tp53-proficient colon cancer cancer cell line in culture (PMID: 25700705).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4586,
                "therapyName": "Trifluridine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6509,
                    "pubMedId": 25700705,
                    "title": "Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25700705"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5285,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK283071 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3815,
                "therapyName": "Doxorubicin + GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4979,
                    "pubMedId": 25658463,
                    "title": "WIP1 phosphatase as a potential therapeutic target in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25658463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18039,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 50% (5/10) of patients with TP53 wild-type multiple myeloma (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8249,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9542,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 (MI-77301) induced p53 signaling and inhibited tumor growth in patient-derived xenograft models of endocrine therapy-resistant breast cancer with wild-type TP53, and induced cell-cycle arrest and inhibited growth of patient-derived endocrine therapy-resistant breast cancer cells in culture (PMID: 27765850).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7266,
                    "pubMedId": 27765850,
                    "title": "Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765850"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11081,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9071,
                    "pubMedId": null,
                    "title": "Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187803.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9315,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO6839921 and Doxil combination treatment demonstrated sustained survival benefit in TP53 wild-type fibrosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4967,
                "therapyName": "Pegylated liposomal-doxorubicin + RO6839921",
                "synonyms": null
            },
            "indication": {
                "id": 3355,
                "name": "fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7077,
                    "pubMedId": null,
                    "title": "Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10720,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors, particularly those with TP53 wild-type liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and a median progression-free survival in LPS of 237 days (PMID: 28240971).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3153,
                "therapyName": "MK-8242",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8785,
                    "pubMedId": 28240971,
                    "title": "Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28240971"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8570,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically induced apoptosis in TP53 wild-type but not TP53 mutated colorectal cancer cell lines in culture, and demonstrated anti-tumor activity in TP53 wild-type but not TP53 mutated patient-derived xenograft models (PMID: 26272063).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11085,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 50749,
                "name": "peripheral T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9071,
                    "pubMedId": null,
                    "title": "Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187803.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8250,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) activated Tp53 signaling, resulting in growth inhibition of TP53 wild-type breast cancer cells in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5284,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK283071 and Paraplatin (carboplatin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3814,
                "therapyName": "Carboplatin + GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4979,
                    "pubMedId": 25658463,
                    "title": "WIP1 phosphatase as a potential therapeutic target in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25658463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5570,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CTX-1 induced cell death in several solid tumor cell lines with wild-type TP53 in culture (PMID: 26883273).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3899,
                "therapyName": "CTX-1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5110,
                    "pubMedId": 26883273,
                    "title": "Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26883273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 232,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I and Phase II clinical trials, various forms of p53 gene therapy (such as adenoviral-p53) have been shown to be generally safe and have demonstrated clinical efficacy in patients with ovarian cancer (PMID: 12082455; PMID: 19621448; PMID: 21927947; PMID: 15297186; PMID: 12082456).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 978,
                "therapyName": "Ad.p53-DC vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 33,
                    "pubMedId": 12082455,
                    "title": "A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12082455"
                },
                {
                    "id": 34,
                    "pubMedId": 12082456,
                    "title": "Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12082456"
                },
                {
                    "id": 35,
                    "pubMedId": 15297186,
                    "title": "A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15297186"
                },
                {
                    "id": 39,
                    "pubMedId": 19621448,
                    "title": "Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19621448"
                },
                {
                    "id": 58,
                    "pubMedId": 21927947,
                    "title": "A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21927947"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8093,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) induced activation of Tp53 target genes and inhibited growth of a non-small cell lung cancer (NSCLC) cell line with wild-type TP53 in culture and inhibited tumor growth in a TP53 wild-type NSCLC cell line xenograft model (PMID: 25567130).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8135,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of KRT-232 (AMG 232) and Paraplatin (carboplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4638,
                "therapyName": "Carboplatin + KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10708,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APR-246 inhibited growth of TP53 wild-type melanoma cells in 3D culture and in cell line xenograft models (PMID: 21239882).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8774,
                    "pubMedId": 21239882,
                    "title": "PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21239882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 838,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, patients with advanced solid tumor harboring TP53 mutations had increased progression-free survival and overall survival than TP53 wild-type patients after treatment with Votrient (pazopanib) in combination with Zolinza (vorinostat) (J Clin Oncol 32:5s, 2014 (suppl; abstr 2576)).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1211,
                "therapyName": "Pazopanib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 481,
                    "pubMedId": null,
                    "title": "A phase I trial of pazopanib and vorinostat: The role of TP53 mutations.",
                    "url": "http://meetinglibrary.asco.org/content/132490-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8259,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type colon cancer cells in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5583,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3900,
                "therapyName": "CTX-1 + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5110,
                    "pubMedId": 26883273,
                    "title": "Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26883273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11749,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Roscovotine (seliciclib) induced substantial apoptosis in non-small cell lung carcinoma cells overexpressing wild-type TP53 in culture (PMID: 22862161).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 609,
                    "pubMedId": 22862161,
                    "title": "Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22862161"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10714,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of TP53 wild-type lung large cell carcinoma (PMID: 22624712).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3405,
                "therapyName": "NSC319726",
                "synonyms": null
            },
            "indication": {
                "id": 4556,
                "name": "lung large cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4308,
                    "pubMedId": 22624712,
                    "title": "Allele-specific p53 mutant reactivation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22624712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8253,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type melanoma cells in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13949,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of SAR405838 (MI-773) and Platinol (cisplatin) resulted in increased Tp53 and Mdm2 expression, and demonstrated improved efficacy over either agent alone in TP53 wild-type patient-derived xenograft (PDX) models of salivary gland adenoid cystic carcinoma, resulting in tumor regression without tumor rebound after cessation of therapy (PMID: 27550999).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 5351,
                "therapyName": "Cisplatin + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 4866,
                "name": "salivary gland adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7920,
                    "pubMedId": 27550999,
                    "title": "Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550999"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4646,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CPUY201112 reduced viability and induced apoptosis in an osteosarcoma cell line with wild-type TP53 in culture, and had a limited effect on an osteosarcoma cell line lacking TP53 (PMID: 26743233).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3589,
                "therapyName": "CPUY201112",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4657,
                    "pubMedId": 26743233,
                    "title": "CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10721,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with TP53 wild-type advanced solid tumors, particularly those with liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and 75.6% (31/41) of patients achieving stable disease (PMID: 28240971).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3153,
                "therapyName": "MK-8242",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 8785,
                    "pubMedId": 28240971,
                    "title": "Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28240971"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11086,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ALRN-6924 treatment in a patient with Merkel cell carcinoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 3965,
                "name": "Merkel cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9071,
                    "pubMedId": null,
                    "title": "Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187803.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1790,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 inhibited growth of TP53 wild-type prostate cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1886,
                    "pubMedId": 25145672,
                    "title": "SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25145672"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10735,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment increased Tp53 and Cdkn1a protein levels, resulted in growth inhibition of TP53 wild-type endometrioid ovary carcinoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2999,
                "therapyName": "thioureidobutyronitrile",
                "synonyms": null
            },
            "indication": {
                "id": 5828,
                "name": "endometrioid ovary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8790,
                    "pubMedId": null,
                    "title": "Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies",
                    "url": "http://www.abstractsonline.com/pp8/#!/4292/presentation/3876"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9316,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2155,
                "therapyName": "RO6839921",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7077,
                    "pubMedId": null,
                    "title": "Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5578,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CTX-1 improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3899,
                "therapyName": "CTX-1",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5110,
                    "pubMedId": 26883273,
                    "title": "Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26883273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8258,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type breast cancer cells in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14105,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALRN-6924 inhibited growth of cells derived from patients with TP53 wild-type acute myeloid leukemia in culture, and inhibited leukemia cell growth, prolonged survival in cell line xenograft models (PMID: 29643228).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11462,
                    "pubMedId": 29643228,
                    "title": "Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29643228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 842,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Adavosertib (MK-1775) and Gemzar (gemcitabine) induced cell death in a variety of sarcoma cell lines and inhibited tumor growth in a patient-derived sarcoma xenograft model, independent of TP53 mutational status (PMID: 23520471).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1279,
                "therapyName": "Adavosertib + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 484,
                    "pubMedId": 23520471,
                    "title": "Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23520471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8257,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type melanoma cells in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4555,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3537,
                "therapyName": "CEP-8983 + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4605,
                    "pubMedId": 23428903,
                    "title": "Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23428903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8260,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type osteosarcoma cells in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 433,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1039,
                "therapyName": "p53-SLP vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 39,
                    "pubMedId": 19621448,
                    "title": "Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19621448"
                },
                {
                    "id": 48,
                    "pubMedId": 21328579,
                    "title": "Long-term clinical and immunological effects of p53-SLP\u00ae vaccine in patients with ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21328579"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4644,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CPUY201112 reduced viability and induced apoptosis in a colon cancer cell line with wild-type TP53 in culture, and had a limited effect on a colon cancer cell line lacking TP53 (PMID: 26743233).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3589,
                "therapyName": "CPUY201112",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4657,
                    "pubMedId": 26743233,
                    "title": "CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5769,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3925,
                "therapyName": "Prodigiosin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5150,
                    "pubMedId": 26759239,
                    "title": "Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated \u0394Np73 Inhibition and p73 Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759239"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8252,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type colon cancer cells in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8254,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type osteosarcoma cells in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5282,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3735,
                "therapyName": "GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4979,
                    "pubMedId": 25658463,
                    "title": "WIP1 phosphatase as a potential therapeutic target in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25658463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18035,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial,  KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 100% (10/10) of patients with TP53 wild-type well-differentiated liposarcomas (WDLPS) and 70% (7/10) of patients with TP53 wild-type de-differentiated liposarcomas, with median duration of 3.9 and 2.0 months respectively, and one patient with WDLPS achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11088,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9071,
                    "pubMedId": null,
                    "title": "Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas",
                    "url": "http://abstracts.asco.org/199/AbstView_199_187803.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8133,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of KRT-232 (AMG 232) and Platinol (cisplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone, resulting in tumor stasis (PMID: 25567130).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4637,
                "therapyName": "Cisplatin + KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8256,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11033,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a TP53 wild-type dedifferentiated papillary thyroid carcinoma cell line treated with APG-115 demonstrated decreased cell viability and induction of cell cycle arrest and apoptosis in culture, and tumor growth suppression and tumor regression in xenograft models (PMID: 28498808).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 5826,
                "therapyName": "APG-115",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9032,
                    "pubMedId": 28498808,
                    "title": "Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28498808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13948,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with SAR405838 (MI-773) resulted in activation of Mdm2 and Tp53 in patient-derived salivary gland adenoid cystic carcinoma (ACC) cells in culture, and led to induction of apoptosis and tumor regression in ACC patient-derived xenograft (PDX) models with wild-type TP53 (PMID: 26936915).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 4866,
                "name": "salivary gland adenoid cystic carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6351,
                    "pubMedId": 26936915,
                    "title": "Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936915"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9985,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HDM201 treatment resulted in tumor regression in various cell line xenograft models of Tp53 wild-type tumors (Cancer Res 2016;76(14 Suppl):Abstract nr 4855).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 2186,
                "therapyName": "HDM201",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7836,
                    "pubMedId": null,
                    "title": "Discovery of NVP-HDM201 - First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/4855"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9312,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma multiforme (GBM) cell lines with amplification of MDM2 and wild-type TP53 demonstrated sensitivity to RG7112 in culture, resulting in decreased viability and restoration of Tp53 signaling, and treatment with RG7112 resulted in growth inhibition in MDM2-amplified TP53 wild-type GBM cell line xenograft models (PMID: 26482041).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2076,
                "therapyName": "RG7112",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7072,
                    "pubMedId": 26482041,
                    "title": "Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482041"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1098,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) inhibited tumor growth in osteosarcoma cell line xenograft models with wild-type TP53 and MDM2 amplification (PMID: 25567130, PMID: 24967612).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 835,
                    "pubMedId": 24967612,
                    "title": "Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24967612"
                },
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8138,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of KRT-232 (AMG 232) and Adriamycin (doxorubicin) inhibited tumor growth and induced tumor regression in an MDM2-amplifed TP53 wild-type osteosarcoma cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 4636,
                "therapyName": "Doxorubicin + KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1788,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 inhibited growth of TP53 wild-type, MDM2 amplified osteosarcoma in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1886,
                    "pubMedId": 25145672,
                    "title": "SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25145672"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9025,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 decreased viability and induced cell cycle arrest in MDM2-amplified dedifferentiated liposarcoma cell lines with wild-type TP53 in culture, and induced TP53 pathway activation and tumor regression in xenograft models (PMID: 26475335).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6874,
                    "pubMedId": 26475335,
                    "title": "SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26475335"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18037,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 62.5% (10/16) of patients with TP53 wild-type, MDM2 amplified solid tumors other than liposarcoma, glioblastoma, and breast cancer, with a median duration of 3.3 months, and a patient with squamous cell carcinoma achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18036,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial,  KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 60% (6/10) of patients with TP53 wild-type, MDM2 amplified glioblastoma, with a median duration of 1.8 months (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8140,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of KRT-232 (AMG 232) and Camptosaur (irinotecan) inhibited tumor growth in a TP53 wild-type colorectal cancer cell line xenograft model, which also harbors a KRAS mutation, with increased efficacy over either agent alone (PMID: 25567130).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 4639,
                "therapyName": "Irinotecan + KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8094,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) induced activation of Tp53 target genes and inhibited growth of a colorectal cancer (CRC) cell line with wild-type TP53, that also harbored a KRAS mutation, in culture and inhibited tumor growth in a TP53 wild-type KRAS-mutant CRC cell line xenograft model (PMID: 25567130).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9935,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Mekinist (trametinib), and CGM097 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 5319,
                "therapyName": "Alpelisib + CGM097 + Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1443,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 1773,
                "therapyName": "ABT-737 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1293,
                    "pubMedId": 21468686,
                    "title": "Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21468686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17730,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, SAR405838 and Pimasertib (MSC1936369B) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 63% (15/24) of patients with TP53 wild-type advanced solid tumors harboring RAS/RAF mutations (KRAS, n=24; BRAF, n=1; NRAS, n=1) (PMID: 30585255; NCT01985191).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 8599,
                "therapyName": "Pimasertib + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15755,
                    "pubMedId": 30585255,
                    "title": "A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30585255"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14101,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALRN-6924 induced apoptosis and inhibited growth of TP53 wild-type acute myeloid leukemia cell lines with elevated Mdm4 expression in culture (PMID: 29643228).",
            "molecularProfile": {
                "id": 2644,
                "profileName": "MDM4 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11462,
                    "pubMedId": 29643228,
                    "title": "Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29643228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7729,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAH-p53-8 in combination with Zelboraf (vemurafenib) resulted in enhanced growth inhibition of TP53 wild-type melanoma cells over expressing MDM4 in culture (PMID: 22820643).",
            "molecularProfile": {
                "id": 2644,
                "profileName": "MDM4 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4554,
                "therapyName": "SAH-p53-8 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1453,
                    "pubMedId": 22820643,
                    "title": "MDM4 is a key therapeutic target in cutaneous melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22820643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1533,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAH-p53-8 treatment of TP53 wild-type melanoma cells over expressing MDM4 inhibited growth in culture and in xenograft models (PMID: 22820643).",
            "molecularProfile": {
                "id": 2644,
                "profileName": "MDM4 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 1836,
                "therapyName": "SAH-p53-8",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1453,
                    "pubMedId": 22820643,
                    "title": "MDM4 is a key therapeutic target in cutaneous melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22820643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1787,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 2285,
                "therapyName": "CGM097 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7241,
                    "pubMedId": null,
                    "title": "Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/5466"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8097,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17731,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, SAR405838 and Pimasertib (MSC1936369B) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 63% (15/24) of patients with TP53 wild-type advanced solid tumors harboring RAS/RAF mutations (KRAS, n=24; BRAF, n=1; NRAS, n=1) (PMID: 30585255; NCT01985191).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 8599,
                "therapyName": "Pimasertib + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15755,
                    "pubMedId": 30585255,
                    "title": "A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30585255"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9933,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 5317,
                "therapyName": "CGM097 + Dabrafenib + Navitoclax + PF-04217903",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3669,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI2536 and Metformin worked synergistically to induce apoptosis and inhibit growth of PLK1-over expressing prostate cancer cells with wild-type TP53 in cell culture and in PDX models (PMID: 25505174).",
            "molecularProfile": {
                "id": 14280,
                "profileName": "PLK1 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 3223,
                "therapyName": "BI2536 + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10286,
                "name": "prostate carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3947,
                    "pubMedId": 25505174,
                    "title": "Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4360,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",
            "molecularProfile": {
                "id": 17823,
                "profileName": "RB1 wild-type TP53 wild-type"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4353,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",
            "molecularProfile": {
                "id": 17823,
                "profileName": "RB1 wild-type TP53 wild-type"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 3459,
                "name": "breast carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4356,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",
            "molecularProfile": {
                "id": 17823,
                "profileName": "RB1 wild-type TP53 wild-type"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4362,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",
            "molecularProfile": {
                "id": 17823,
                "profileName": "RB1 wild-type TP53 wild-type"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4354,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",
            "molecularProfile": {
                "id": 17823,
                "profileName": "RB1 wild-type TP53 wild-type"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 1520,
                "name": "colon carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4731,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).",
            "molecularProfile": {
                "id": 18879,
                "profileName": "ALK F1174L TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4735,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK, wild-type TP53, and MDM2 amplification (PMID: 26438783).",
            "molecularProfile": {
                "id": 18882,
                "profileName": "ALK wild-type MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4732,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).",
            "molecularProfile": {
                "id": 18883,
                "profileName": "ALK F1245C TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4733,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).",
            "molecularProfile": {
                "id": 18886,
                "profileName": "ALK act mut TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4736,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).",
            "molecularProfile": {
                "id": 18888,
                "profileName": "ALK mut TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4740,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).",
            "molecularProfile": {
                "id": 18891,
                "profileName": "ALK amp TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4741,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).",
            "molecularProfile": {
                "id": 18892,
                "profileName": "ALK wild-type TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5038,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of Nutlin-3 treatment in TP53 wild-type breast cancer cells harboring PPM1D amplification resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20109,
                "profileName": "PPM1D amp TP53 wild-type"
            },
            "therapy": {
                "id": 3736,
                "therapyName": "GSK2830371 + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5040,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of Nutlin-3 treatment in TP53 wild-type colorectal cancer cells harboring a PPM1D activating mutation, resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20109,
                "profileName": "PPM1D amp TP53 wild-type"
            },
            "therapy": {
                "id": 3736,
                "therapyName": "GSK2830371 + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5039,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of RG7388 treatment in TP53 wild-type breast cancer cells harboring PPM1D amplification resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20109,
                "profileName": "PPM1D amp TP53 wild-type"
            },
            "therapy": {
                "id": 3737,
                "therapyName": "GSK2830371 + Idasanutlin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5036,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 treatment, which requires an intact P53 response, inhibited the growth of a breast cancer cell line harboring PPM1D amplification and TP53 wild-type (PMID: 24390428).",
            "molecularProfile": {
                "id": 20109,
                "profileName": "PPM1D amp TP53 wild-type"
            },
            "therapy": {
                "id": 3735,
                "therapyName": "GSK2830371",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4845,
                    "pubMedId": 24390428,
                    "title": "Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24390428"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5044,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of RG7388 treatment in TP53 wild-type osteosarcoma cells harboring a PPM1D activating mutation, resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20192,
                "profileName": "PPM1D act mut TP53 wild-type"
            },
            "therapy": {
                "id": 3737,
                "therapyName": "GSK2830371 + Idasanutlin",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5041,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of RG7388 treatment in TP53 wild-type colorectal cancer cells harboring a PPM1D activating mutation, resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20192,
                "profileName": "PPM1D act mut TP53 wild-type"
            },
            "therapy": {
                "id": 3737,
                "therapyName": "GSK2830371 + Idasanutlin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5043,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of Nutlin-3 treatment in TP53 wild-type osteosarcoma cancer cells harboring a PPM1D activating mutation, resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20192,
                "profileName": "PPM1D act mut TP53 wild-type"
            },
            "therapy": {
                "id": 3736,
                "therapyName": "GSK2830371 + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8567,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).",
            "molecularProfile": {
                "id": 26360,
                "profileName": "KRAS G13D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8568,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",
            "molecularProfile": {
                "id": 26361,
                "profileName": "BRAF V600E PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8569,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",
            "molecularProfile": {
                "id": 26362,
                "profileName": "BRAF V600E PTEN loss TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8581,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",
            "molecularProfile": {
                "id": 26369,
                "profileName": "KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type"
            },
            "therapy": {
                "id": 4771,
                "therapyName": "PD-0325901 + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8703,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8702,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8601,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",
            "molecularProfile": {
                "id": 26376,
                "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8704,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",
            "molecularProfile": {
                "id": 26377,
                "profileName": "KRAS G12V PIK3CA E545K TP53 wild-type"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8603,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",
            "molecularProfile": {
                "id": 26377,
                "profileName": "KRAS G12V PIK3CA E545K TP53 wild-type"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8705,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",
            "molecularProfile": {
                "id": 26377,
                "profileName": "KRAS G12V PIK3CA E545K TP53 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6689,
                    "pubMedId": 26272063,
                    "title": "MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26272063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a neuroblastoma cell line over expressing MDM2 and wild-type for TP53 demonstrated sensitivity to treatment with MX69 in culture, resulting in decreased cell survival (PMID: 27666947).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4775,
                "therapyName": "MX69",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6705,
                    "pubMedId": 27666947,
                    "title": "Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27666947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8625,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MX69 treatment induced cell death and inhibited cell growth in a TP53 wild-type acute lymphocytic leukemia cell line over expressing MDM2, and prolonged survival in xenograft models (PMID: 27666947).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4775,
                "therapyName": "MX69",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6705,
                    "pubMedId": 27666947,
                    "title": "Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27666947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9314,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type, MDM2 over-expressing osteosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 2155,
                "therapyName": "RO6839921",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7077,
                    "pubMedId": null,
                    "title": "Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13088,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AQ-101 inhibited growth and induced apoptosis in acute lymphocytic leukemia (ALL) cell lines with wild-type TP53 and overexpression of MDM2 in culture, and inhibited development of leukemia in ALL cell line xenograft models (PMID: 29282301).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 6682,
                "therapyName": "AQ-101",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10752,
                    "pubMedId": 29282301,
                    "title": "Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29282301"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-5461 inhibited anchorage-independent growth and induced cell death in prostate cancer cells with high Myc expression and functional TP53 in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26817,
                "profileName": "MYC over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4963,
                "therapyName": "CX-5461",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9323,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 induced cell cycle arrest in prostate cancer cells with high Myc expression and functional TP53 in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26817,
                "profileName": "MYC over exp TP53 wild-type"
            },
            "therapy": {
                "id": 3675,
                "therapyName": "CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9326,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in enhanced cell cycle arrest compared to single agent in prostate cancer cells with high Myc expression and functional TP53 in culture (PMID: 27486174).",
            "molecularProfile": {
                "id": 26817,
                "profileName": "MYC over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4969,
                "therapyName": "CX-5461 + CX-6258",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7070,
                    "pubMedId": 27486174,
                    "title": "The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27486174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9313,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human glioblastoma multiforme cell lines with gain or amplification of MDM4 and wild-type TP53 demonstrated sensitivity to RG7112 in culture, resulting in decreased cell viability (PMID: 26482041).",
            "molecularProfile": {
                "id": 26818,
                "profileName": "MDM4 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2076,
                "therapyName": "RG7112",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7072,
                    "pubMedId": 26482041,
                    "title": "Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482041"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9547,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 (MI-77301) inhibited tumor growth in an endocrine-resistant patient-derived xenograft (PDX) model of breast cancer with high ESR1-over expression and wild-type TP53 (PMID: 27765850).",
            "molecularProfile": {
                "id": 26889,
                "profileName": "ESR1 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7266,
                    "pubMedId": 27765850,
                    "title": "Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765850"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9546,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Falsodex (fulvestrant) and SAR405838 (MI-77301) inhibited tumor growth in an endocrine-resistant patient-derived xenograft (PDX) model of breast cancer with high ESR1-over expression and wild-type TP53, but did not demonstrate increased efficacy over SAR405838 (MI-77301) alone (PMID: 27765850).",
            "molecularProfile": {
                "id": 26889,
                "profileName": "ESR1 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 5068,
                "therapyName": "Fulvestrant + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7266,
                    "pubMedId": 27765850,
                    "title": "Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765850"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9545,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Falsodex (fulvestrant) and SAR405838 (MI-77301) inhibited tumor growth in an endocrine-resistant patient-derived xenograft (PDX) model of breast cancer harboring ESR1-YAP1 and wild-type TP53, and had an increased effect on tumor growth delay following treatment cessation compared to SAR405838 (MI-77301) alone (PMID: 27765850).",
            "molecularProfile": {
                "id": 26890,
                "profileName": "ESR1 - YAP1 TP53 wild-type"
            },
            "therapy": {
                "id": 5068,
                "therapyName": "Fulvestrant + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7266,
                    "pubMedId": 27765850,
                    "title": "Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765850"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17732,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, SAR405838 and Pimasertib (MSC1936369B) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 63% (15/24) of patients with TP53 wild-type advanced solid tumors harboring RAS/RAF mutations (KRAS, n=24; BRAF, n=1; NRAS, n=1) (PMID: 30585255; NCT01985191).",
            "molecularProfile": {
                "id": 32774,
                "profileName": "NRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 8599,
                "therapyName": "Pimasertib + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15755,
                    "pubMedId": 30585255,
                    "title": "A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30585255"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 642,
            "profileName": "TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2169,
            "profileName": "MDM2 amp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2521,
            "profileName": "KRAS mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2644,
            "profileName": "MDM4 over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 3307,
            "profileName": "BRAF mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14280,
            "profileName": "PLK1 over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17823,
            "profileName": "RB1 wild-type TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18878,
            "profileName": "ALK R1275Q TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18879,
            "profileName": "ALK F1174L TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18882,
            "profileName": "ALK wild-type MDM2 amp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18883,
            "profileName": "ALK F1245C TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18886,
            "profileName": "ALK act mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18888,
            "profileName": "ALK mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18891,
            "profileName": "ALK amp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18892,
            "profileName": "ALK wild-type TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20109,
            "profileName": "PPM1D amp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20192,
            "profileName": "PPM1D act mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24186,
            "profileName": "EGFR exon 19 del TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25399,
            "profileName": "MDM2 pos TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26360,
            "profileName": "KRAS G13D PIK3CA H1047R TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26361,
            "profileName": "BRAF V600E PIK3CA H1047R TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26362,
            "profileName": "BRAF V600E PTEN loss TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26369,
            "profileName": "KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26376,
            "profileName": "KRAS G12D PIK3CA H1047R TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26377,
            "profileName": "KRAS G12V PIK3CA E545K TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26380,
            "profileName": "MDM2 over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26817,
            "profileName": "MYC over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26818,
            "profileName": "MDM4 amp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26889,
            "profileName": "ESR1 over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26890,
            "profileName": "ESR1 - YAP1 TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30806,
            "profileName": "TET2 inact mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30807,
            "profileName": "TET2 loss TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32246,
            "profileName": "SMARCA4 mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32247,
            "profileName": "SMARCA4 loss TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32248,
            "profileName": "SMARCB1 mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32249,
            "profileName": "SMARCB1 loss TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32774,
            "profileName": "NRAS mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}